Skip to main content
Journal cover image

No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis.

Publication ,  Journal Article
Paller, AS; Fölster-Holst, R; Chen, SC; Diepgen, TL; Elmets, C; Margolis, DJ; Pollock, BH
Published in: J Am Acad Dermatol
August 2020

BACKGROUND: Long-term safety of topical calcineurin inhibitors is not well understood. APPLES (A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis; NCT00475605) examined incidence of lymphoma and other cancers in a pediatric population with atopic dermatitis. OBJECTIVE: To quantify incident malignancies during 10 years in children with atopic dermatitis who used topical tacrolimus for ≥6 weeks. METHODS: Standardized incidence ratios for cancer events were analyzed relative to sex-, age-, and race-matched control data from national cancer registries. RESULTS: There were 7954 eligible patients enrolled at 314 sites in 9 countries. During 44,629 person-years, 6 confirmed incident cancers occurred (standardized incidence ratio, 1.01; 95% confidence interval, 0.37-2.20). No lymphomas occurred. LIMITATIONS: Observational prospective cohort study. CONCLUSION: The cancer incidence was as expected, given matched background data. This finding provides no support for the hypothesis that topical tacrolimus increases long-term cancer risk in children with atopic dermatitis.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Acad Dermatol

DOI

EISSN

1097-6787

Publication Date

August 2020

Volume

83

Issue

2

Start / End Page

375 / 381

Location

United States

Related Subject Headings

  • Tacrolimus
  • Sex Factors
  • Risk Factors
  • Risk Assessment
  • Registries
  • Prospective Studies
  • Neoplasms
  • Male
  • Longitudinal Studies
  • Infant
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Paller, A. S., Fölster-Holst, R., Chen, S. C., Diepgen, T. L., Elmets, C., Margolis, D. J., & Pollock, B. H. (2020). No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol, 83(2), 375–381. https://doi.org/10.1016/j.jaad.2020.03.075
Paller, Amy S., Regina Fölster-Holst, Suephy C. Chen, Thomas L. Diepgen, Craig Elmets, David J. Margolis, and Brad H. Pollock. “No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis.J Am Acad Dermatol 83, no. 2 (August 2020): 375–81. https://doi.org/10.1016/j.jaad.2020.03.075.
Paller AS, Fölster-Holst R, Chen SC, Diepgen TL, Elmets C, Margolis DJ, et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol. 2020 Aug;83(2):375–81.
Paller, Amy S., et al. “No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis.J Am Acad Dermatol, vol. 83, no. 2, Aug. 2020, pp. 375–81. Pubmed, doi:10.1016/j.jaad.2020.03.075.
Paller AS, Fölster-Holst R, Chen SC, Diepgen TL, Elmets C, Margolis DJ, Pollock BH. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol. 2020 Aug;83(2):375–381.
Journal cover image

Published In

J Am Acad Dermatol

DOI

EISSN

1097-6787

Publication Date

August 2020

Volume

83

Issue

2

Start / End Page

375 / 381

Location

United States

Related Subject Headings

  • Tacrolimus
  • Sex Factors
  • Risk Factors
  • Risk Assessment
  • Registries
  • Prospective Studies
  • Neoplasms
  • Male
  • Longitudinal Studies
  • Infant